BIOMAT Database Logo BIOMAT Database Logo

Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic hepatitis B. 2016

Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Gata Haydarpasa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.

Quantitative hepatitis B surface antigen (HBsAg) is a valuable tool in hepatitis B virus (HBV) disease diagnosis and management for evaluating the effectiveness of antiviral therapy. The aim of the current research was to compare the performances of the Elecsys HBsAg II and Abbott Architect HBsAg assays in chronic hepatitis B (CHB) patients. Between May 2014 and December 2014, 72 CHBs were tested using Abbott Architect HBsAg QT and Roche Elecsys HBsAg II assay. After transformation to log (10) IU/mL, the results of the two assays were compared using the interclass correlation test, the Pearson correlation test and Bland-Altman analyses. We also analyzed all the parameters in on-treatment patients and naive patients with Pearson correlation test. There was a significant overall correlation between the Elecsys and Architect assays. We also analyzed all the parameters in naive and on-treatment patients. There was a significantly good correlation between the two assays in untreated patients and on-treatment patients. In this study, there was a significant correlation between the results of the Elecsys HBsAg II and Abbott Architect HBsAg assays in the overall and naive/on-treatment CHB patients. Additionally, we found that mean HBsAg levels resulting from the Architect assay were higher than those obtained by Elecsys assay.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D005260 Female Females
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients.
January 2015, Biomedical journal,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.
January 2015, Clinical laboratory,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.
April 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
February 2012, Clinical and vaccine immunology : CVI,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen.
November 2021, Medicina (Kaunas, Lithuania),
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays.
June 2013, Journal of viral hepatitis,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Multicentre evaluation of the Elecsys hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays.
November 2009, Medical microbiology and immunology,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg).
May 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Frequency of hepatitis B surface antigen variants (HBsAg) in hepatitis B virus genotype B and C infected East- and Southeast Asian patients: Detection by the Elecsys® HBsAg II assay.
June 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Ergenekon Karagoz, and Mehmet Burak Selek, and Alpaslan Tanoglu, and Mustafa Hatipoglu, and Asim Ulçay, and Vedat Turhan
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
April 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Copied contents to your clipboard!